These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21361734)

  • 1. Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel.
    de Ronde W; Vogel S; Bui HN; Heijboer AC
    Pharmacotherapy; 2011 Mar; 31(3):248-52. PubMed ID: 21361734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers.
    DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ
    Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel testosterone 2% gel for the treatment of hypogonadal males.
    Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y
    J Androl; 2012; 33(4):601-7. PubMed ID: 21979302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections.
    Rochira V; Balestrieri A; Madeo B; Granata AR; Carani C
    J Androl; 2006; 27(2):165-75. PubMed ID: 16278367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voice changes after androgen therapy for hypogonadotrophic hypogonadism.
    Akcam T; Bolu E; Merati AL; Durmus C; Gerek M; Ozkaptan Y
    Laryngoscope; 2004 Sep; 114(9):1587-91. PubMed ID: 15475787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone.
    Rosenthal BD; May NR; Metro MJ; Harkaway RC; Ginsberg PC
    Urology; 2006 Mar; 67(3):571-4. PubMed ID: 16527581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
    Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
    Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone improves erectile function in hypogonadal patients with venous leakage.
    Kurbatov D; Kuznetsky J; Traish A
    J Androl; 2008; 29(6):630-7. PubMed ID: 18599885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparability of single measurements of serum testosterone to the 24-hour C(avg) in patients using testosterone 2% solution.
    Muram D; Baygani S
    J Sex Med; 2014 Nov; 11(11):2826-9. PubMed ID: 25123851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.